{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:37:35Z","timestamp":1792193855152,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Prediction of inpatients with community-acquired pneumonia (CAP) at high risk for severe adverse events (SAEs) requiring higher-intensity treatment is critical. However, evidence regarding prediction rules applicable to all patients with CAP including those with healthcare-associated pneumonia (HCAP) is limited. The objective of this study is to develop and validate a new prediction system for SAEs in inpatients with CAP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Logistic regression analysis was performed in 1334 inpatients of a prospective multicenter study to develop a multivariate model predicting SAEs (death, requirement of mechanical ventilation, and vasopressor support within 30\u00a0days after diagnosis). The developed ALL-COP-SCORE rule based on the multivariate model was validated in 643 inpatients in another prospective multicenter study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The ALL-COP SCORE rule included albumin (&lt;\u20092\u00a0g\/dL, 2 points; 2\u20133\u00a0g\/dL, 1 point), white blood cell (&lt;\u20094000 cells\/\u03bcL, 3 points), chronic lung disease (1 point), confusion (2 points), PaO<jats:sub>2<\/jats:sub>\/F<jats:sub>I<\/jats:sub>O<jats:sub>2<\/jats:sub> ratio (&lt;\u2009200\u00a0mmHg, 3 points; 200\u2013300\u00a0mmHg, 1 point), potassium (\u2265\u20095.0\u00a0mEq\/L, 2 points), arterial pH (&lt;\u20097.35, 2 points), systolic blood pressure (&lt;\u200990\u00a0mmHg, 2 points), PaCO<jats:sub>2<\/jats:sub> (&gt;\u200945\u00a0mmHg, 2 points), HCO<jats:sub>3<\/jats:sub><jats:sup>\u2212<\/jats:sup> (&lt;\u200920\u00a0mmol\/L, 1 point), respiratory rate (\u2265\u200930 breaths\/min, 1 point), pleural effusion (1 point), and extent of chest radiographical infiltration in unilateral lung (&gt;\u20092\/3, 2 points; 1\/2\u20132\/3, 1 point). Patients with 4\u20135, 6\u20137, and\u2009\u2265\u20098 points had 17%, 35%, and 52% increase in the probability of SAEs, respectively, whereas the probability of SAEs was 3% in patients with\u2009\u2264\u20093 points. The ALL-COP SCORE rule exhibited a higher area under the receiver operating characteristic curve (0.85) compared with the other predictive models, and an ALL-COP SCORE threshold of\u2009\u2265\u20094 points exhibited 92% sensitivity and 60% specificity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>ALL-COP SCORE rule can be useful to predict SAEs and aid in decision-making on treatment intensity for all inpatients with CAP including those with HCAP. Higher-intensity treatment should be considered in patients with CAP and an ALL-COP SCORE threshold of\u2009\u2265\u20094 points.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>\n                           <jats:italic>Trial registration<\/jats:italic>\n                        <\/jats:title>\n                <jats:p>This study was registered with the University Medical Information Network in Japan, registration numbers UMIN000003306 and UMIN000009837.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-022-01819-0","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T15:04:52Z","timestamp":1641999892000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A prediction rule for severe adverse events in all inpatients with community-acquired pneumonia: a multicenter observational study"],"prefix":"10.1186","volume":"22","author":[{"given":"Toshihiro","family":"Sakakibara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Saka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"key":"1819_CR1","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1086\/511159","volume":"44","author":"LA Mandell","year":"2007","unstructured":"Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, et al. Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27\u201372.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1819_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJM199701233360402","volume":"336","author":"MJ Fine","year":"1997","unstructured":"Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243\u201350.","journal-title":"N Engl J Med"},{"issue":"5","key":"1819_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/thorax.58.5.377","volume":"58","author":"WS Lim","year":"2003","unstructured":"Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377\u201382.","journal-title":"Thorax"},{"issue":"7","key":"1819_CR4","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45\u201367.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"1819_CR5","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1164\/rccm.200602-177OC","volume":"174","author":"PP Espana","year":"2006","unstructured":"Espana PP, Capelastegui A, Gorordo I, Esteban C, Oribe M, Ortega M, Bilbao A, Quintana JM. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med. 2006;174(11):1249\u201356.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"1819_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1086\/589754","volume":"47","author":"PG Charles","year":"2008","unstructured":"Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, Wright AA, Ramirez JA, Christiansen KJ, Waterer GW, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47(3):375\u201384.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1819_CR7","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00134-011-2261-x","volume":"37","author":"JD Chalmers","year":"2011","unstructured":"Chalmers JD, Mandal P, Singanayagam A, Akram AR, Choudhury G, Short PM, Hill AT. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med. 2011;37(9):1409\u201320.","journal-title":"Intensive Care Med"},{"issue":"4","key":"1819_CR8","doi-asserted-by":"publisher","first-page":"R141","DOI":"10.1186\/cc11447","volume":"16","author":"C Marti","year":"2012","unstructured":"Marti C, Garin N, Grosgurin O, Poncet A, Combescure C, Carballo S, Perrier A. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care. 2012;16(4):R141.","journal-title":"Crit Care"},{"issue":"2","key":"1819_CR9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s00134-010-2077-0","volume":"37","author":"S Ewig","year":"2011","unstructured":"Ewig S, Woodhead M, Torres A. Towards a sensible comprehension of severe community-acquired pneumonia. Intensive Care Med. 2011;37(2):214\u201323.","journal-title":"Intensive Care Med"},{"issue":"5","key":"1819_CR10","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O\u2019Grady NP, Bartlett JG, Carratala J, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61\u2013111.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1819_CR11","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1164\/rccm.201301-0079OC","volume":"188","author":"Y Shindo","year":"2013","unstructured":"Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, Goto Y, Fukui Y, Iwaki M, Okumura J, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2013;188(8):985\u201395.","journal-title":"Am J Respir Crit Care Med"},{"key":"1819_CR12","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.2147\/IDR.S165669","volume":"11","author":"D Kobayashi","year":"2018","unstructured":"Kobayashi D, Shindo Y, Ito R, Iwaki M, Okumura J, Sakakibara T, Yamaguchi I, Yagi T, Ogasawara T, Sugino Y, et al. Validation of the prediction rules identifying drug-resistant pathogens in community-onset pneumonia. Infect Drug Resist. 2018;11:1703\u201313.","journal-title":"Infect Drug Resist"},{"issue":"9","key":"1819_CR13","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1473-3099(15)00151-6","volume":"15","author":"Y Shindo","year":"2015","unstructured":"Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Goto Y, Fukui Y, Iwaki M, Okumura J, Yamaguchi I, et al. Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort study. Lancet Infect Dis. 2015;15(9):1055\u201365.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"1819_CR14","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/resp.13232","volume":"23","author":"J Okumura","year":"2018","unstructured":"Okumura J, Shindo Y, Takahashi K, Sano M, Sugino Y, Yagi T, Taniguchi H, Saka H, Matsui S, Hasegawa Y, et al. Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: Impact of beta-lactam plus macrolide combination therapy. Respirology. 2018;23(5):526\u201334.","journal-title":"Respirology"},{"issue":"4","key":"1819_CR15","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","volume":"171","author":"American Thoracic Society","year":"2005","unstructured":"American Thoracic Society. Infectious Diseases Society of America: guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388\u2013416.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1819_CR16","first-page":"1260","volume":"127","author":"TJ Marrie","year":"2005","unstructured":"Marrie TJ, Wu L. Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest. 2005;127(4):1260\u201370.","journal-title":"Chest"},{"issue":"5","key":"1819_CR17","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1378\/chest.12-0576","volume":"142","author":"E Laserna","year":"2012","unstructured":"Laserna E, Sibila O, Aguilar PR, Mortensen EM, Anzueto A, Blanquer JM, Sanz F, Rello J, Marcos PJ, Velez MI, et al. Hypocapnia and hypercapnia are predictors for ICU admission and mortality in hospitalized patients with community-acquired pneumonia. Chest. 2012;142(5):1193\u20139.","journal-title":"Chest"},{"issue":"18","key":"1819_CR18","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1001\/jama.1990.03450180053028","volume":"264","author":"JJ Escarce","year":"1990","unstructured":"Escarce JJ, Kelley MA. Admission source to the medical intensive care unit predicts hospital death independent of APACHE II score. JAMA. 1990;264(18):2389\u201394.","journal-title":"JAMA"},{"issue":"1","key":"1819_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32\u20135.","journal-title":"Cancer"},{"issue":"3","key":"1819_CR20","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1183\/09031936.00089513","volume":"43","author":"W Salih","year":"2014","unstructured":"Salih W, Schembri S, Chalmers JD. Simplification of the IDSA\/ATS criteria for severe CAP using meta-analysis and observational data. Eur Respir J. 2014;43(3):842\u201351.","journal-title":"Eur Respir J"},{"issue":"6","key":"1819_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/cid\/cir463","volume":"53","author":"JD Chalmers","year":"2011","unstructured":"Chalmers JD, Taylor JK, Mandal P, Choudhury G, Singanayagam A, Akram AR, Hill AT. Validation of the Infectious Diseases Society of America\/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis. 2011;53(6):503\u201311.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"1819_CR22","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1136\/thx.2008.109785","volume":"64","author":"S Ewig","year":"2009","unstructured":"Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H, Schraeder P, Welte T, Hoeffken G. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax. 2009;64(12):1062\u20139.","journal-title":"Thorax"},{"issue":"8","key":"1819_CR23","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.ajem.2018.10.044","volume":"37","author":"B Ehsanpoor","year":"2019","unstructured":"Ehsanpoor B, Vahidi E, Seyedhosseini J, Jahanshir A. Validity of SMART-COP score in prognosis and severity of community acquired pneumonia in the emergency department. Am J Emerg Med. 2019;37(8):1450\u20134.","journal-title":"Am J Emerg Med"},{"issue":"10","key":"1819_CR24","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1136\/thx.2009.133280","volume":"65","author":"JD Chalmers","year":"2010","unstructured":"Chalmers JD, Singanayagam A, Akram AR, Mandal P, Short PM, Choudhury G, Wood V, Hill AT. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax. 2010;65(10):878\u201383.","journal-title":"Thorax"},{"issue":"10","key":"1819_CR25","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1136\/thx.2009.134072","volume":"65","author":"YK Loke","year":"2010","unstructured":"Loke YK, Kwok CS, Niruban A, Myint PK. Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis. Thorax. 2010;65(10):884\u201390.","journal-title":"Thorax"},{"issue":"4","key":"1819_CR26","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1164\/ajrccm.158.4.9803114","volume":"158","author":"S Ewig","year":"1998","unstructured":"Ewig S, Ruiz M, Mensa J, Marcos MA, Martinez JA, Arancibia F, Niederman MS, Torres A. Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med. 1998;158(4):1102\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1819_CR27","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1164\/rccm.2102084","volume":"166","author":"DC Angus","year":"2002","unstructured":"Angus DC, Marrie TJ, Obrosky DS, Clermont G, Dremsizov TT, Coley C, Fine MJ, Singer DE, Kapoor WN. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med. 2002;166(5):717\u201323.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1819_CR28","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/thx.2003.008110","volume":"59","author":"S Ewig","year":"2004","unstructured":"Ewig S, de Roux A, Bauer T, Garcia E, Mensa J, Niederman M, Torres A. Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax. 2004;59(5):421\u20137.","journal-title":"Thorax"},{"issue":"2","key":"1819_CR29","doi-asserted-by":"publisher","first-page":"R54","DOI":"10.1186\/cc7781","volume":"13","author":"B Renaud","year":"2009","unstructured":"Renaud B, Labarere J, Coma E, Santin A, Hayon J, Gurgui M, Camus N, Roupie E, Hemery F, Herve J, et al. Risk stratification of early admission to the intensive care unit of patients with no major criteria of severe community-acquired pneumonia: development of an international prediction rule. Crit Care. 2009;13(2):R54.","journal-title":"Crit Care"},{"issue":"4","key":"1819_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00408-013-9467-3","volume":"191","author":"TT Bauer","year":"2013","unstructured":"Bauer TT, Welte T, Strauss R, Bischoff H, Richter K, Ewig S. Why do nonsurvivors from community-acquired pneumonia not receive ventilatory support? Lung. 2013;191(4):417\u201324.","journal-title":"Lung"},{"key":"1819_CR31","doi-asserted-by":"publisher","first-page":"j2471","DOI":"10.1136\/bmj.j2471","volume":"358","author":"RG Wunderink","year":"2017","unstructured":"Wunderink RG, Waterer G. Advances in the causes and management of community acquired pneumonia in adults. BMJ. 2017;358:j2471.","journal-title":"BMJ"},{"issue":"1","key":"1819_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1378\/chest.13-1531","volume":"146","author":"S Gattarello","year":"2014","unstructured":"Gattarello S, Borgatta B, Sol\u00e9-Viol\u00e1n J, Vall\u00e9s J, Vidaur L, Zaragoza R, Torres A, Rello J. Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000\u20132013). Chest. 2014;146(1):22\u201331.","journal-title":"Chest"},{"issue":"1","key":"1819_CR33","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1183\/09031936.00188710","volume":"39","author":"R Menendez","year":"2012","unstructured":"Menendez R, Torres A, Reyes S, Zalacain R, Capelastegui A, Aspa J, Borderias L, Martin-Villasclaras JJ, Bello S, Alfageme I, et al. Initial management of pneumonia and sepsis: factors associated with improved outcome. Eur Respir J. 2012;39(1):156\u201362.","journal-title":"Eur Respir J"},{"issue":"2","key":"1819_CR34","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/CCM.0b013e3182a66b9b","volume":"42","author":"WI Sligl","year":"2014","unstructured":"Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med. 2014;42(2):420\u201332.","journal-title":"Crit Care Med"},{"issue":"3","key":"1819_CR35","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","volume":"43","author":"A Rhodes","year":"2017","unstructured":"Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304\u201377.","journal-title":"Intensive Care Med"},{"issue":"2","key":"1819_CR36","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ajem.2017.07.083","volume":"36","author":"YN Ni","year":"2018","unstructured":"Ni YN, Luo J, Yu H, Liu D, Liang BM, Liang ZA. The effect of high-flow nasal cannula in reducing the mortality and the rate of endotracheal intubation when used before mechanical ventilation compared with conventional oxygen therapy and noninvasive positive pressure ventilation. A systematic review and meta-analysis. Am J Emerg Med. 2018;36(2):226\u201333.","journal-title":"Am J Emerg Med"},{"issue":"10303","key":"1819_CR37","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S0140-6736(21)00630-9","volume":"398","author":"S Aliberti","year":"2021","unstructured":"Aliberti S, Dela Cruz CS, Amati F, Sotgiu G, Restrepo MI. Community-acquired pneumonia. Lancet. 2021;398(10303):906\u201319.","journal-title":"Lancet"},{"issue":"1","key":"1819_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41572-021-00259-0","volume":"7","author":"A Torres","year":"2021","unstructured":"Torres A, Cilloniz C, Niederman MS, Menendez R, Chalmers JD, Wunderink RG, van der Poll T. Pneumonia. Nat Rev Dis Primers. 2021;7(1):25.","journal-title":"Nat Rev Dis Primers"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-01819-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-022-01819-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-01819-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T15:05:51Z","timestamp":1641999951000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-022-01819-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1819"],"URL":"https:\/\/doi.org\/10.1186\/s12890-022-01819-0","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,12]]},"assertion":[{"value":"19 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol adhered to the Declaration of Helsinki and the Japanese Ethics Guidelines for Epidemiological Studies. The study was approved by the ethics committee of Nagoya University and respective institutional review boards of the participating institutions. Informed consent of the participants was waived, but the opt-out method was adopted according to the ethics guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All of the following information provide relevant financial activities outside the submitted work. Dr. Shindo reports personal fees (payment for lectures including service on speakers bureaus) from Pfizer Inc., Shionogi & Co., Ltd., MSD K.K., Taisho Toyama Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., Sawai Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc., AstraZeneca K.K., KYORIN Pharmaceutical Co.,Ltd., DAIICHI SANKYO COMPANY, LIMITED, and Nippon Boehringer Ingelheim Co., Ltd. Dr. Yagi reports grants and personal fees (payment for lectures including service on speakers bureaus) from Taisho Toyama Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Pfizer Inc., Daiichi Sankyo Co., Ltd., Meiji Seika Pharma Co., Ltd., MSD K.K., Dainippon Sumitomo Pharma Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Pfizer Inc., Asahi Kasei Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Meiji Seika Pharma Co., Ltd., Astellas Pharma Inc., Dainippon Sumitomo Pharma Co., Ltd., Mitsubishi Tanabe Pharma., MSD K.K, Beckton Dickinson and Company, Saraya Co., Ltd., KYORIN Pharmaceutical Co.,Ltd., Beckman Coulter, Inc., TERUMO CORPORATION, Oxford Immunotec Ltd., MIYARISAN PHARMACEUTICAL CO., Kao Professional Services, and Kyowa Hakko Kirin Co., Ltd. Dr. Saka reports grants from Taisho Toyama Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Pfizer Inc., Chugai Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Bristol-Myers Squibb Company, Kyowa Hakko Kirin Co., Ltd., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Boehringer Ingelheim Co., Ltd., MSD K.K., Eli Lilly Japan K. K., Daiichi Sankyo CO., LTD., Astrazeneca K. K., Novartis Phama K. K., Taiho Pharmaceutical Co., LTD., Sanofi K. K., and Bayer Yakuhin, Ltd. Dr. Hasegawa reports grants and personal fees (payment for lectures including service on speakers bureaus) from Chugai Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., MSD K.K., and Pfizer Japan Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}